News
- FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Ollie’s Bargain Outlet (OLLI) Investors of Tomorrow’s Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact Its Attorneys
15:00 - GlobeNewswire
-
- Guess & Co. Corporation Announces Management Re-Alignment
14:47 - GlobeNewswire
-
- 9-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching
14:30 - GlobeNewswire
-
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ADTRAN (ADTN) Investors with Significant Losses to Contact Its Attorneys, Application Deadline is Approaching
14:17 - GlobeNewswire
-
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Pareteum (TEUM) Investors with $500k+ Losses to Contact Its Attorneys, Application Deadline is Approaching
13:49 - GlobeNewswire
-
- Certainty During Uncertain Times: Guess & Co. Corporation Launches Nationwide Advertising Campaign
11:20 - GlobeNewswire
-
- CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
00:58 - GlobeNewswire
-
- BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
11/16/2019 / 23:30 - GlobeNewswire
-
- Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
11/16/2019 / 21:59 - GlobeNewswire
-
- Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
11/16/2019 / 18:00 - GlobeNewswire
Real-time